PULSE the living trend engine
▲ Peaking Business

EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials

A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.

5sources
5articles
14velocity
+0%since first seen
3h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

A US House committee is investigating Merck and AbbVie regarding their involvement with clinical drug trials conducted in China. Coverage indicates that the investigation centers on the ties between these Chinese trial sites and the country's military.

Specifically, the House China panel has also questioned Bristol Myers Squibb and Pfizer concerning their selection and use of clinical trial sites within the region. Future developments depend on the responses provided by these companies to the House panel's inquiries.

Coverage does not yet specify the timeline for these investigations or the specific nature of the materials requested by the committee.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 2h ago.

Quick answers

Which companies are currently under investigation by the US House committee?

The investigation involves Merck, AbbVie, Pfizer, and Bristol Myers Squibb.

What is the focus of the investigation?

The committee is examining clinical drug trials conducted at sites in China that are reportedly tied to the country's military.

Are there other companies being questioned?

Yes, coverage indicates the House China panel has also questioned Bristol Myers and Pfizer regarding their trial sites.

Coverage (5)

Topics

Merck AbbVie Pfizer Bristol Myers Squibb China US Congress

Related trends